<DOC>
	<DOCNO>NCT00376792</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , docetaxel , work different way stop growth tumor cell , either kill cell stop divide . Giving docetaxel surgery may kill tumor cell remain surgery . Sometimes , surgery , tumor may need treatment progress . In case , observation may sufficient . It yet know whether give docetaxel surgery effective observation treat prostate cancer . PURPOSE : This randomized phase III trial study docetaxel see well work compare observation treat patient undergone radical prostatectomy prostate cancer .</brief_summary>
	<brief_title>Docetaxel Compared With Observation Treating Patients Who Have Undergone Radical Prostatectomy Prostate Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Compare time prostate-specific antigen ( PSA ) progression patient margin-positive tumor undergo radical prostatectomy high-grade prostate cancer treat docetaxel versus observation . Secondary - Compare PSA double time patient treat regimen . - Compare quality life patient . - Compare overall metastasis-free survival patient treat regimen . OUTLINE : This prospective , open-label , randomize , multicenter study . Patients stratify accord participate center tumor stage ( pT2 v pT3 ) . Patients randomize 1 2 treatment arm . - Arm I : Patients receive docetaxel IV 1 hour day 1 . Treatment repeat every 21 day 6 course absence disease progression unacceptable toxicity . Quality life assess baseline , directly 6 month complete study treatment , annually thereafter . - Arm II : Patients undergo observation PSA progression ( define PSA ≥ 0.5 ng/mL ) Quality life assess baseline , week 19 , annually thereafter . After completion study treatment , patient follow periodically 5 year . PROJECTED ACCRUAL : A total 396 patient accrue study .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm adenocarcinoma prostate meet one follow criterion undergo radical prostatectomy : pT2 Gleason score 4+3 810 positive margin radical prostatectomy specimen Any pT3a tumor Gleason score ≥ 4+3 pT3b tumor Gleason score ≥ 7 Negative lymph node histological examination ( N0 ) Patients preoperative prostatespecific antigen ( PSA ) ≥ 10.0 ng/mL undergone lymph node dissection Postoperative PSA must &lt; 0.5 ng/mL Considered high risk recurrent disease No metastatic ( M0 ) disease Negative bone scan PATIENT CHARACTERISTICS : WHO/ECOG performance status 01 Hemoglobin ≥ 11.0 g/dL Neutrophil count ≥ 1,500/mm³ Platelet count ≥ 150,000/mm³ Creatinine ≤ 1.5 time upper limit normal ( ULN ) Bilirubin normal AST ALT ≤ 1.5 time ULN Alkaline phosphatase &lt; 1.5 time ULN No active untreated infectious disease ( e.g. , tuberculosis methicillinresistant Staphylococcus aureus ) No active gastric ulcer No known hypersensitivity polysorbate 80 No symptomatic peripheral neuropathy ≥ grade 2 No myocardial infarction within past 6 month No unstable cardiovascular disease within past 6 month No serious illness medical condition No alter psychological physical state would preclude study compliance No malignancy within past 5 year except basal cell squamous cell skin cancer PRIOR CONCURRENT THERAPY : See Disease Characteristics No prior hormonal therapy ( e.g. , luteinizing hormonereleasing hormone analogue and/or antiandrogens ) affect prostate cancer cell No prior radiotherapy pelvis No prior chemotherapy More 6 month since prior systemic corticosteroid No concurrent anticancer therapy investigational drug</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>June 2009</verification_date>
	<keyword>stage IIB prostate cancer</keyword>
	<keyword>stage IIA prostate cancer</keyword>
	<keyword>stage III prostate cancer</keyword>
	<keyword>adenocarcinoma prostate</keyword>
</DOC>